Ceftolozane-Tazobactam

C difficile risk
High
Oral Bioavailability
N/A

Dosing

Requires AMS review within 72 hours. See below for more information.

  • Dosed as a sum of ceftolozane and tazobactam (e.g. 1.5 g = 1 g ceftolozane + 0.5 g tazobactam)

1.5 g IV q8h

3 g IV q8h

CrCl > 50 mL/minCrCl 30 - 50 mL/minCrCl < 30 mL/minNo renal adjustment required750 mg IV q8h 375 mg IV q8h

CrCl > 50 mL/minCrCl 30 - 50 mL/minCrCl < 30 mL/minNo renal adjustment required1.5 g IV q8h 750 mg IV q8h

Most IndicationsPulmonary Indications750 mg IV x 1, then 150 mg IV q8h

  • Give dose after dialysis on HD days2.25 g IV x 1, then 450 mg IV q8h

  • Give dose after dialysis on HD days

No data

General Information

Infections caused by multidrug-resistant Gram-negative bacteria, specifically ESBL-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa when other treatment alternatives are not an option

Laboratory should be asked to perform sensitivity testing

CSF penetration: Insufficient data

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.